TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04954196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT administration: On Day 1 of the cycle, HRT is planned in accordance with the department's standard practice.~* The frozen embryo transfer will be performed 6 days after progesterone initiation.~* The HRT will be maintained until the pregnancy test is performed: If the test is positive, HRT will be continued for up to 12 weeks of amenorrhea at the same doses and then gradually stopped. If the test is negative, HRT will be stopped gradually~Placebo administration:On the day of the first monitoring Dm (corresponding to D13-D16 of the cycle), a single per os dose of placebo (Microcrystalline cellulose) is taken at night, neither the patient nor the investigator knows what drug is the patient getting. Monitoring is systematically performed the next morning.. The treatment will be maintained until the pregnancy test is performed, then if the test is positive, the treatment will be maintained for a total duration of 7 weeks.
Study: NCT06034288
Drug: Xeomin 100 UNT Injection
Normalized name: Xeomin 100 UNT Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravesical injection
Study: NCT06034288
Drug: Botox 100 UNT Injection
Normalized name: Botox 100 UNT Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravesical injection
Study: NCT05642585
Drug: MY008211A tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral
Study: NCT05642585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral
Study: NCT06675994
Drug: PCSK9 Antibody, PCSK9 Enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-vitro demonstration of the direct effect if the PCSK9 enzyme on platelets. The study will use commercially available recombinant PCSK9 enzyme to promote platelet activity and the PCSK9 antibody to inhibit activity. In each patient, platelet function testing will occur in the absence of PCSK9 enzyme, after the addition of PCSK9 enzyme, and after the addition of both PCSK9 enzyme and antibody reagent to the blood sample prior to testing.
Study: NCT06676410
Drug: Dispensing Codivir®
Approvals — FDA: no, EMA: no, PMDA: no
Description: the participant receives Codivir®
Study: NCT06676410
Drug: Antiretrovirals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir - inhibits HIV-1 reverse transcriptase activity by competing with the natural substrate, deoxyadenosine 5'-triphosphate and, upon incorporation into DNA, causes DNA chain termination.~* Lamivudine - potent selective inhibitor of HIV-1 and HIV-2 replication in vitro.~* Darunavir - prevents the formation of mature infective viral particles, indicated for the treatment of the human immunodeficiency virus (HIV), which causes AIDS.~* Ritonavir: antiretroviral protease inhibitor, widely used in combination with other protease inhibitors in the therapy and prevention of HIV infection, which causes the syndrome acquired immunodeficiency (AIDS).~* Single solid formulation (in 1 tablet) 1x/day with:~* Tenofovir (TDF) 300 mg~* Lamivudine (3TC) 300 mg~* Darunavir (DRV) 800 mg, 1x/day~* Ritonavir (RTV) 100 mg, 1x/day
Study: NCT05069051
Drug: standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients obtain the standard of care: combination rituximab and venetoclax
Study: NCT05557344
Drug: Acetaminophen IV
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An IV infusion of 15mg/kg of acetaminophen (PrACETAMINOPHEN INJECTION, AVIR Pharma Inc.) (maximum single dose:1g) will be administered regularly every 6h as a 15-minute intravenous infusion. At the same time, an oral placebo with similar appearance as the corresponding acetaminophen oral solution will be administered.
Study: NCT05557344
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A liquid oral acetaminophen suspension will be administered regularly every 6h at a dose of 15mg/kg (maximum single dose: 1g). An IV infusion of NaCl 0.9% corresponding to the volume of IV acetaminophen will be administered as a 15-minute intravenous infusion at the same time as the oral dose. PrACETAMINOPHEN INJECTION ® is a clear and colorless liquid undistinguishable from NaCl 0.9%.
Study: NCT05173883
Drug: injection ，CU-20401
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection，cohort A 6 sites
Study: NCT05173883
Drug: injection ，placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection，just one site
Study: NCT05076552
Drug: TACH101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally via capsules
Study: NCT06139315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05011812
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match
Study: NCT05047341
Drug: SHR0302、[14C]SHR0302
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg SHR0302/ 80 µCi \[14C\]SHR0302, once, D1
Study: NCT04881318
Drug: Medications that modulate heart rate and blood pressure
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications that modulate heart rate and blood pressure that participants regularly take. These medications include beta-blockers, midodrine, ivabradine and stimulants.
Study: NCT04802811
Drug: SHR2150；Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose；SHR2150-dose 1 or Placebo-dose 1
Study: NCT04802811
Drug: SHR2150；Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose；SHR2150-dose 2 or Placebo-dose 2
Study: NCT04802811
Drug: SHR2150；Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose；SHR2150-dose 3 or Placebo-dose 3
Study: NCT04802811
Drug: SHR2150；Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose；SHR2150-dose 4 or Placebo-dose 4
Study: NCT04802811
Drug: SHR2150；Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose；SHR2150-dose 5 or Placebo-dose 5
Study: NCT06151522
Drug: Alpha-Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT06151522
Drug: α-adrenergic receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT06287931
Drug: Ursodoxycholic acid group
Normalized name: ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodoxycholic acid, 250mg po tid x 6 months
Study: NCT06151548
Drug: THYROX (Atlantic krill oil).
Approvals — FDA: no, EMA: no, PMDA: no
Description: The daily content of krill oil is 2000 mg, including omega-3 fatty acids 350 mg, EPA - 240 mg, DHA - 110 mg, phospholipids - 800 mg, astaxanthin 200 mg.
Study: NCT06151548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control capsules will be made of olive oil of equal size and color.
Study: NCT05579223
Drug: Intrathecal Placebo Mono Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 5% glucose injection. Administration: subarachnoid space mono bolus inject, 1.5ml, Speed ≤ 0.5 ml/s
Study: NCT05445895
Drug: Renexin CR 200/160mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renexin CR 200/160mg will be added to Aspirin 100mg
Study: NCT05936671
Drug: Sevoflurane and remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: For anesthetic maintenance, balanced anesthesia with sevoflurane inhalation and target controlled infusion of remifentanil will be performed.
Study: NCT06172686
Drug: Doxycycline (100mg tablets strength as Doxycycline Hyclate) will also be administered orally and will be given as 1 tablet (100mg) Once daily for 7 days.
Approvals — FDA: no, EMA: no, PMDA: no
Description: The second arm will receive Doxycycline (100mg tablets strength as Doxycycline hyclate) that will also be administered orally. Sub-curative regimen will be given as 1 tablet (100mg) once daily for 7 days.
Study: NCT06357910
Drug: HCP2303
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 1 tablet once per period
Study: NCT06357910
Drug: RLD2102
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 1 tablet once per period
Study: NCT05481775
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 25mg/m2 + Cisplatin 25mg/m2 QW
Study: NCT05481775
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: consolidation Immunotherapy (Tislelizhu 200mg iv. drip, Q3W, up to 12 months.)
Study: NCT06422650
Drug: Nigella Sativa capsule 500mg
Normalized name: Nigella sativa seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella Sativa capsule 500mg twice daily for 8 weeks
Study: NCT06422650
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo identical to astaxanthin
Study: NCT04573803
Drug: Phenytoin Sodium
Normalized name: Phenytoin Sodium
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosing will be as prescribed clinically by the treating physician. Phenytoin Sodium may be administered orally, intravenously or via nasogastric tube.
Study: NCT04645446
Drug: Pro-ocular gel
Normalized name: Denticare Pro Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months
Study: NCT04645446
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months
Study: NCT05528055
Drug: SCR-6920 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCR-6920 capsule will be oral administered once daily at escalating doses on a continuous basis
Study: NCT05528055
Drug: SCR-6920 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis
Study: NCT05383209
Drug: EYP-1901
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Injection
Study: NCT06139341
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04712669
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 matching placebo tablets on top of standard of care
Study: NCT00539799
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 - 7.5 mg/day
Study: NCT00539799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo to prednisolone
Study: NCT04808778
Drug: Hydroxyurea therapy per standard care
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose of 20mg/kg/day
Study: NCT05658406
Drug: Ringer's Lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion of 15 mL/kg/hour Ringer's lactate intraoperative
Study: NCT05658406
Drug: Ringer's Lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion of 10 mL/kg/hour Ringer's lactate intraoperative .
Study: NCT05658406
Drug: normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard fluid management: 4 ml for 1st 10 kg, 2 ml for the next 10 kg , 1 ml rest of body weight
Study: NCT06316206
Drug: Ethinylestradiol/Dienogest 0.03mg/2mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Ethinylestradiol/Dienogest 0.03mg/2mg at any time of the menstrual cycle
Study: NCT05213676
Drug: Inhaled Nitric Oxide (iNO) use
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: The center will use iNO per their usual protocol in the initial resuscitation period (defined as birth through stabilization and CDH repair). No center will alter any component of their standard clinical practice guideline or protocol governing CDH care.
Study: NCT04925492
Drug: Cu-64]-LLP2A
Approvals — FDA: no, EMA: no, PMDA: no
Description: A radioactive tracer used in PET imaging.
Study: NCT05068076
Drug: Perfluorobutane
Normalized name: Perfluorobutane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfluorobutane enhanced ultrasound will be done prior to ablation of HCC and after 2hours post ablation and comparison will be done with 1 month post procedure CT/MRI
Study: NCT05884268
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients scheduled for elective LC will receive placebo venlafaxine before surgery
Study: NCT00316641
Drug: Lipid-lowing Tea
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06373744
Drug: cyclophosphamide , methotrexate , vinorelbine ,capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drugs used in metronomic chemotherapy are cyclophosphamide (CTX), methotrexate (M), vinorelbine (VNR), and capecitabine
Study: NCT05230680
Drug: ACHOP
Normalized name: ACHOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Phase I Azacitidine D-2\~D1, starting from dose level 1. Based on the BOIN design described above, if no DLT is identified in level 1, the dose will be escalated stepwise to levels 2, 3, and then 4.~   Azacitidine combined with CHOP regimen every 3 weeks as below:~  * Level 1 - Azacitidine 50mg/m2 D-2, -1, 1~  * Level 2 - Azacitidine 75mg/m2 D-2, -1, 1~  * Level 3 - Azacitidine 100mg/m2 D-2, -1, 1~  * Level 4 - Azacitidine 125mg/m2 D-2, -1, 1~   Azacitidine at each level will be combined with the corresponding CHOP regimen as follows:~  * Cyclophosphamide 750mg/m2 d1~  * Doxorubicin 50 mg/m2 d1~  * Vincristine 1.4 mg/m2 (Max: 2 mg) d1~  * Prednisolone 100mg PO d1-5~2. Phase II~   * Azacitidine determined dose daily for D-2, -1, 1~  * CHOP (Cyclophosphamide 750mg/m2 d1, Doxorubicin 50 mg/m2 d1, Vincristine 1.4 mg/m2 (Max: 2 mg) d1, Prednisolone 100mg PO d1-5), 6 cycles in total
Study: NCT06259058
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m² on Day 1 of a 14-day cycle
Study: NCT05470387
Drug: LB1148
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 700 mL of drug product will be administered orally as a split dose before surgery.
Study: NCT05470387
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 700 mL of placebo will be administered orally as a split dose before surgery.
Study: NCT06318897
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by IV
Study: NCT06318897
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV
Study: NCT05180695
Drug: HDM201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: A dose escalation part with the aim to assess the safety of the proposed combination. Eligible patients will be treated with a fixed dose of pazopanib (800mg/d, continuously) and escalating doses of HDM201. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent.~Part 2: An extension part with a fixed dose of pazopanib (800mg/d, continuously) and the recommended phase 2 dose of HDM201 determined during the dose escalation part. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent.
Study: NCT04199728
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection pen
Study: NCT05201404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control arm
Study: NCT05745311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT00005674
Drug: Creatine
Normalized name: Creatine
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05783206
Drug: MIR 19 ®
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIR 19 ® contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use.~In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs.
Study: NCT05502913
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recipients will undergo bowel preconditioning with antibiotics (Rifaximin) following randomization.
Study: NCT05756504
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection ketorolac 30 mg IV x TDS will be given to each patient in each group.
Study: NCT05826275
Drug: TGN-S11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small Molecule
Study: NCT05932277
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05932277
Drug: Flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06194734
Drug: KC1036
Approvals — FDA: no, EMA: no, PMDA: no
Description: KC1036 60mg QD orally, before a meal, continuous administration, 21 days as a cycle
Study: NCT05489406
Drug: F/TAF TOS (3 x 60/7.5 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60/7.5 mg TOS emtricitabine/TAF
Study: NCT00034463
Drug: folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05608343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Difamilast (Study drug) ointment without active ingradient
Study: NCT03749850
Drug: LTLD
Normalized name: Levodopa and Carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive up to six cycles at three-weeks intervals of:~* Intravenous LTLD dosed at 50mg/m2 administered during the MR-HIFU treatment~* 60 minutes of MR-HIFU mild local hyperthermia at 40 °C - 42 °C to the primary breast tumour~* Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment~In case of toxicity, LTLD, cyclophosphamide and/or hyperthermia dosages will be adjusted as specified in the study protocol.
Study: NCT03749850
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive up to six cycles at three-weeks intervals of:~- Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment~In case of toxicity, cyclophosphamide dosages will be adjusted as specified in the study protocol.
Study: NCT04701333
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05011227
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 cycles Gemcitabine based chemotherapy before endoscopic surgery, with or without after surgery
Study: NCT00962481
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05622656
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium Chloride Solution
Study: NCT04984070
Drug: Oral Contraceptives, Combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: One of the three medications like ethinylestradiol (35 μg) and cyproterone acetate, drospirenone and ethinylestradiol tablets (I) and (Ⅱ) will be used as an antiandrogen.
Study: NCT04878198
Drug: Melatonin supplement intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This intervention is a 10-week melatonin supplement intervention where melatonin supplement will be provided 30 minutes before bedtime.
Study: NCT05375188
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOSAGE FORM: IV Infusion DOSAGE: Equal Volume
Study: NCT05844449
Drug: VNZ/TEZ/D-IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablets for oral administration.
Study: NCT06020898
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with acute ischemic stroke included in the study are randomly assigned to low-dose sodium valproate group, high-dose sodium valproate group and placebo group. Besides receiving conventional treatment for stroke, 10mg/kg sodium valproate, 20mg/kg sodium valproate or normal saline were given intravenously for 3 consecutive days, respectively.
Study: NCT05055544
Drug: Bearberry
Normalized name: bearberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single dose of placebo powder dissolved in 75 ml water and 2 bearberry tablets t.i.d. for 7 days (group B).
Study: NCT05625334
Drug: non-enteric-coated chewable aspirin
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Orally administered
Study: NCT05174065
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT05803850
Drug: HNC1058 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: HNC1058 Capsules/Placebos, single dose, PO, starting dose of 10 mg escalating up to 80 mg；HNC1058 Capsules/Placebos, 50 mg, single dose, FED.
Study: NCT04835870
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide-750 mg/m2 i.v d1 (/21d)
Study: NCT04835870
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin-50 mg/m2 i.v d1 (/21d)
Study: NCT05839574
Drug: MTX monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX in a single dose of 100 mg intravenously and 50 mg in intra-amniotic injection (day 0), along with 30 mg potassium chloride in case of positive fetal heartbeat (FH), and subsequent hysteroscopic evacuation of products of conception (POC)
Study: NCT05567822
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the placebo group, patients will receive a bolus dose of normal saline followed by a continuous infusion of normal saline intraoperatively
Study: NCT04706962
Drug: TH1902
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT05206149
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo (represented by isotonic saline solution) is administered.